Tags

Type your tag names separated by a space and hit enter

Perspectives for novel mixed diruthenium-organic drugs as metallopharmaceuticals in cancer therapy.
Anticancer Agents Med Chem. 2010 May; 10(4):312-23.AA

Abstract

Ruthenium compounds have been actively studied as metallodrugs for cancer therapy. Representatives of ruthenium-based antitumor drugs are the classes of ruthenium(III)-chlorido-(N-ligand) complexes, including the drugs namely NAMI-A and KP1019 in clinical trials, and ruthenium(II)-arene organometallics, with some compounds currently undergoing advanced preclinical testing. An alternative approach for tumor-inhibiting metallodrugs is the coordination of metal ions to organic pharmaceuticals. The combination of antitumor-active ruthenium ion with biologically-active pro-ligands in single compounds can result in the enhancement of activity, for example through synergistic effects. In the present article, some developments in the ruthenium-based antitumor drugs field are briefly highlighted and recent studies on mixed diruthenium-organic drugs as metallopharmaceuticals in cancer therapy are described. Novel organic pharmaceuticals-containing diruthenium(II,III) complexes have shown promising antitumor activity for C6 rat glioma - a model for glioblastoma multiforme (GBA).

Authors+Show Affiliations

Department of Inorganic Chemistry, Institute of Chemistry, University of São Paulo, São Paulo, SP, Brazil. deosilva@iq.usp.br

Pub Type(s)

Journal Article
Research Support, Non-U.S. Gov't
Review

Language

eng

PubMed ID

20380636

Citation

Silva, Denise de Oliveira. "Perspectives for Novel Mixed Diruthenium-organic Drugs as Metallopharmaceuticals in Cancer Therapy." Anti-cancer Agents in Medicinal Chemistry, vol. 10, no. 4, 2010, pp. 312-23.
Silva Dde O. Perspectives for novel mixed diruthenium-organic drugs as metallopharmaceuticals in cancer therapy. Anticancer Agents Med Chem. 2010;10(4):312-23.
Silva, D. d. e. . O. (2010). Perspectives for novel mixed diruthenium-organic drugs as metallopharmaceuticals in cancer therapy. Anti-cancer Agents in Medicinal Chemistry, 10(4), 312-23.
Silva Dde O. Perspectives for Novel Mixed Diruthenium-organic Drugs as Metallopharmaceuticals in Cancer Therapy. Anticancer Agents Med Chem. 2010;10(4):312-23. PubMed PMID: 20380636.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Perspectives for novel mixed diruthenium-organic drugs as metallopharmaceuticals in cancer therapy. A1 - Silva,Denise de Oliveira, PY - 2010/02/09/received PY - 2010/04/24/accepted PY - 2010/4/13/entrez PY - 2010/4/13/pubmed PY - 2010/8/3/medline SP - 312 EP - 23 JF - Anti-cancer agents in medicinal chemistry JO - Anticancer Agents Med Chem VL - 10 IS - 4 N2 - Ruthenium compounds have been actively studied as metallodrugs for cancer therapy. Representatives of ruthenium-based antitumor drugs are the classes of ruthenium(III)-chlorido-(N-ligand) complexes, including the drugs namely NAMI-A and KP1019 in clinical trials, and ruthenium(II)-arene organometallics, with some compounds currently undergoing advanced preclinical testing. An alternative approach for tumor-inhibiting metallodrugs is the coordination of metal ions to organic pharmaceuticals. The combination of antitumor-active ruthenium ion with biologically-active pro-ligands in single compounds can result in the enhancement of activity, for example through synergistic effects. In the present article, some developments in the ruthenium-based antitumor drugs field are briefly highlighted and recent studies on mixed diruthenium-organic drugs as metallopharmaceuticals in cancer therapy are described. Novel organic pharmaceuticals-containing diruthenium(II,III) complexes have shown promising antitumor activity for C6 rat glioma - a model for glioblastoma multiforme (GBA). SN - 1875-5992 UR - https://www.unboundmedicine.com/medline/citation/20380636/Perspectives_for_novel_mixed_diruthenium_organic_drugs_as_metallopharmaceuticals_in_cancer_therapy_ L2 - http://www.eurekaselect.com/70992/article DB - PRIME DP - Unbound Medicine ER -